Central Nervous System Pharmacology Practice Questions

Q: Which of the following is an antagonist used to reverse the effects of benzodiazepines?

Flumazenil. ***Flumazenil*** - **Flumazenil** is a **competitive antagonist** at the **GABA-A receptor**, specifically binding to the benzodiazepine site. - By blocking benzodiazepines from binding, it rapidly **reverses their sedative and anxiolytic effects**, making it useful in overdose or to awaken patients post-procedure. *Alprazolam* - **Alprazolam** is a **benzodiazepine** itself, acting as a **GABA-A receptor agonist** rather than an antagonist. - It would **potentiate** the effects of other benzodiazepines, leading to increased sedation and respiratory depression, not reversal. *Propofol* - **Propofol** is an **intravenous anesthetic** that works by enhancing the effects of **GABA**, but it is not a specific benzodiazepine antagonist. - It would **deepen sedation** and anesthesia, which is the opposite of reversing benzodiazepine effects. *Naltrexone* - **Naltrexone** is a **mu-opioid receptor antagonist** used to block the effects of opioids in cases of overdose or addiction. - It has **no pharmacological effect** on the benzodiazepine receptor or its actions.

Q: Sodium valproate is not the drug of choice for which of the following seizure types?

Infantile spasms. ***Infantile spasms*** - While valproate can be used as an add-on therapy, it is **not the first-line drug of choice** for infantile spasms, which typically respond better to **ACTH (adrenocorticotropic hormone)** or **vigabatrin**. - Infantile spasms often have a unique **hypsarrhythmia** pattern on EEG and a distinct clinical presentation from other seizure types. *Absence seizures* - Sodium valproate is considered an **effective broad-spectrum antiepileptic drug** used in the treatment of absence seizures. - It works by increasing **GABA concentrations** in the brain, which helps to suppress spike-and-wave discharges characteristic of absence seizures. *Myoclonic seizures* - **Sodium valproate** is a highly effective first-line treatment for various generalized seizure types, including myoclonic seizures. - Its broad mechanism of action, affecting GABAergic and glutamatergic neurotransmission, makes it suitable for these generalized seizure types. *Atonic seizures* - Sodium valproate is a commonly used drug for atonic seizures, especially in the context of **Lennox-Gastaut syndrome**. - It helps to reduce the sudden loss of muscle tone associated with atonic seizures, improving seizure control.

Q: What is the drug of choice for managing status epilepticus?

Lorazepam. ***Lorazepam*** - **Lorazepam** is the preferred first-line agent for status epilepticus due to its rapid onset of action and relatively long duration of anticonvulsant effect (12-24 hours), making it highly effective in stopping ongoing seizures. - Its **lipophilicity** allows it to quickly cross the blood-brain barrier while having less redistribution than diazepam, providing sustained seizure control. - Dose: **0.1 mg/kg IV** (typically 4 mg) administered at 2 mg/min. *Propofol* - **Propofol** is an anesthetic agent used in **refractory status epilepticus** when first and second-line agents have failed. - It carries risks of **hemodynamic instability**, **propofol infusion syndrome** with prolonged use, and requires ICU monitoring with intubation. - Reserved for third-line therapy, not appropriate as initial management. *Thiopentone* - **Thiopentone** is a barbiturate used for **refractory status epilepticus** as a third-line agent. - It has a longer half-life and recovery time compared to benzodiazepines, with significant **cardiovascular depression** and respiratory suppression. - Requires ICU setting with mechanical ventilation and hemodynamic support. *Phenytoin* - **Phenytoin** (or fosphenytoin) is a **second-line agent** used after benzodiazepines if seizures persist. - It has a **slower onset of action** (15-30 minutes) compared to benzodiazepines and requires cardiac monitoring due to risk of arrhythmias. - Loading dose: **20 mg/kg IV** at maximum rate of 50 mg/min to avoid cardiovascular complications.

Q: Which of the following statements about chloral hydrate is false?

Has a sweet taste. ***Has a sweet taste*** - Chloral hydrate has a **bitter, acrid taste**, not a sweet taste. This characteristic taste is often masked in formulations given to patients. - Its unpleasant taste can be a barrier to patient compliance if not properly disguised. *Peculiar pungent odor* - Chloral hydrate is known to have a **characteristic pungent odor**. This is a distinct physical property of the compound. - The odor can be an identifying feature for the substance in its raw form. *Crystalline structure* - Chloral hydrate exists as **colorless or white crystals** in its pure form. This is a common physical state for many organic compounds. - The crystalline structure allows it to be easily dissolved in water and alcohol. *Used as a sedative* - Chloral hydrate is historically and therapeutically used as a **sedative and hypnotic** agent, primarily for short-term treatment of insomnia and for sedation prior to medical procedures. - Its sedative effects are due to its metabolism into **trichloroethanol**, which is the active compound.

Q: Which of the following statements about ramelteon is false?

Has high addiction liability. ***Has high addiction liability*** - Ramelteon is a **melatonin receptor agonist** that does not bind to GABA receptors, distinguishing it from benzodiazepines and Z-drugs (zolpidem, eszopiclone, zaleplon). - Its mechanism of action leads to a **very low risk of abuse and dependence**, contrary to the statement. *Is a substrate of CYP1A2* - Ramelteon is extensively metabolized in the liver, primarily by **CYP1A2**, which is accurate. - This metabolic pathway can lead to drug interactions if co-administered with **CYP1A2 inhibitors** (e.g., fluvoxamine), which can significantly increase ramelteon concentrations. *Approved for treatment of insomnia* - Ramelteon is indeed indicated for the **treatment of insomnia**, particularly for difficulties with **sleep onset**. - It works by mimicking the action of **melatonin**, promoting the regulation of the sleep-wake cycle. *Agonist at MT1 and MT2 receptors* - Ramelteon acts as a **selective agonist** at the **melatonin MT1 and MT2 receptors** in the suprachiasmatic nucleus. - Activation of these receptors helps to modulate the **circadian rhythm**, thereby promoting sleep.

Question 1

Which of the following is an antagonist used to reverse the effects of benzodiazepines?

Accepted Answer

Flumazenil

Answer

Alprazolam

Answer

Naltrexone

Answer

Propofol

Question 2

Sodium valproate is not the drug of choice for which of the following seizure types?

Accepted Answer

Infantile spasms

Answer

Absence seizures

Answer

Myoclonic seizures

Answer

Atonic seizures

Question 3

What is the drug of choice for managing status epilepticus?

Accepted Answer

Lorazepam

Answer

Propofol

Answer

Thiopentone

Answer

Phenytoin

Question 4

Which of the following statements about chloral hydrate is false?

Accepted Answer

Has a sweet taste

Answer

Crystalline structure

Answer

Used as a sedative

Answer

Peculiar pungent odor

Question 5

Which of the following statements about ramelteon is false?

Accepted Answer

Has high addiction liability

Answer

Is a substrate of CYP1A2

Answer

Approved for treatment of insomnia

Answer

Agonist at MT1 and MT2 receptors

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?